| |  Online-Ressource |
|---|
| Verfasst von: | Frost, Nikolaj [VerfasserIn]  |
|---|
| | Bleckmann, Annalen [VerfasserIn] |
|---|
| | Griesinger, Frank [VerfasserIn] |
|---|
| | Grohé, Christian [VerfasserIn] |
|---|
| | Janning, Melanie [VerfasserIn] |
|---|
| | Kollmeier, Jens [VerfasserIn] |
|---|
| | Reinmuth, Niels [VerfasserIn] |
|---|
| | Sebastian, Martin [VerfasserIn] |
|---|
| | Thomas, Michael [VerfasserIn] |
|---|
| | Reck, Martin [VerfasserIn] |
|---|
| Titel: | Rationale and design of the phase II ANTELOPE study of atezolizumab, carboplatin and nab-Paclitaxel vs. pembrolizumab, platinum and pemetrexed in TTF-1 negative, metastatic lung adenocarcinoma (AIO-TRK-0122) |
|---|
| Verf.angabe: | Nikolaj Frost, Annalen Bleckmann, Frank Griesinger, Christian Grohé, Melanie Janning, Jens Kollmeier, Niels Reinmuth, Martin Sebastian, Michael Thomas, Martin Reck |
|---|
| E-Jahr: | 2023 |
|---|
| Jahr: | September 2023 |
|---|
| Umfang: | 5 S. |
|---|
| Fussnoten: | Online verfügbar 23 April 2023, Version des Artikels 22 August 2023 ; Gesehen am 08.12.2023 |
|---|
| Titel Quelle: | Enthalten in: Clinical lung cancer |
|---|
| Ort Quelle: | Dallas, Tex. : Cancer Information Group, 1999 |
|---|
| Jahr Quelle: | 2023 |
|---|
| Band/Heft Quelle: | 24(2023), 6 vom: Sept., Seite 568-572 |
|---|
| ISSN Quelle: | 1938-0690 |
|---|
| Abstract: | Introduction - Pemetrexed-based immunochemotherapy represents an established standard of care as first line treatment for non-oncogenic driven metastatic non-small cell lung adenocarcinoma (NSCLC/ADC). However, retrospective analyses revealed better outcomes for pemetrexed-free regimens compared to pemetrexed-containing regimens in patients with thyroid transcription factor 1 (TTF-1) negative NSCLC/ADC. The multicenter, phase II, randomized, open-label ANTELOPE trial evaluates whether atezolizumab, carboplatin and nab-paclitaxel is superior to pembrolizumab, cis-/carboplatin and pemetrexed in TTF-1 negative NSCLC/ADC. - Methods - Eligible participants are ≥18 years of age, with histologically or cytologically confirmed, treatment-naïve stage IV TTF-1 negative NSCLC/ADC without actionable genomic alterations or PD-L1-overexpression (TPS ≥50%) and will be randomized in a 1:1 fashion to pemetrexed-free (group A) vs. pemetrexed-based (group B) immunochemotherapy. The primary endpoint of this trial is overall survival (OS). - Results - Enrollment will start in Q2 2023 at 30 sites in Germany with a planned inclusion of 136 participants. - Conclusion - ANTELOPE will provide efficacy outcomes of the current standard-of-care for the specific subset of TTF-1 negative NSCLC/ADC in a head-to-head comparison of approved immunochemotherapy regimens. |
|---|
| DOI: | doi:10.1016/j.cllc.2023.04.009 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.cllc.2023.04.009 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S1525730423000761 |
|---|
| | DOI: https://doi.org/10.1016/j.cllc.2023.04.009 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Checkpoint inhibitors |
|---|
| | Clinical trial |
|---|
| | NSCLC |
|---|
| | Predictive biomarker |
|---|
| K10plus-PPN: | 1872331408 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Rationale and design of the phase II ANTELOPE study of atezolizumab, carboplatin and nab-Paclitaxel vs. pembrolizumab, platinum and pemetrexed in TTF-1 negative, metastatic lung adenocarcinoma (AIO-TRK-0122) / Frost, Nikolaj [VerfasserIn]; September 2023 (Online-Ressource)
